Department of Research and Development, BIAL, 4745-457, Trofa, Portugal.
Department of Neurology, ULS Braga, Hospital de Braga, 4710-243, Braga, Portugal; CNS - Campus Neurológico, 4710-452, Braga, Portugal.
Parkinsonism Relat Disord. 2024 Nov;128:107124. doi: 10.1016/j.parkreldis.2024.107124. Epub 2024 Sep 2.
Parkinson's disease (PD) ranks second in global neurodegenerative disorders. The "Parkinson's Real-world Impact assesSMent (PRISM)" study addressed the disease burden and treatment of European PD patients. Yet, the burden on Portuguese PD patients remains unexplored. Here, we outline the demographics, clinical features, and impact of PD in the Portuguese PRISM cohort.
Descriptive analysis of the PRISM Portuguese cohort (80 patients) was performed, emphasizing socio-demographic data, anti-PD medication usage, PD impact on patients' lives and healthcare resources utilization.
The predominant comorbidities in the Portuguese PD cohort (55 % male; mean age 66.2 years; mean disease duration 8.8 years) included depression (26.3 %) and anxiety (26.3 %). Levodopa was the initial prescribed anti-PD medication for 88 % of patients. Among Portuguese PDP, dopamine agonists (DA), monoamine oxidase-B (MAO-B) inhibitors, and catechol-O-methyltransferase (COMT) inhibitors were used by 50 %, 44.4 %, and 18.3 %, respectively. Portuguese PDP experienced impaired quality of life (PDQ-39 score: 31.3 ± 16.8), various non-motor symptoms, namely sadness/blues (65.4 %), urinary urgency (63.5 %), high/low sex interest (57.7 %), while 56 % reported at least one impulse control behavior. Additionally, 30.8 % retired early due to PD and 31.8 % reduced hours in daily activities. Mental health appointments were attended by 31 %, primarily in psychiatry (19 %) and psychology (6 %), and psychotherapy.
This study uncovers the burden of PD among Portuguese patients, revealing current treatment methods, impact on daily life and healthcare resources employed in Portugal. It emphasizes the need for personalized clinical strategies at national and international levels to improve long-term health outcomes and quality of life of PD patients.
帕金森病（PD）在全球神经退行性疾病中排名第二。“帕金森病真实世界影响评估（PRISM）”研究探讨了欧洲 PD 患者的疾病负担和治疗情况。然而，葡萄牙 PD 患者的负担仍未得到探索。在这里，我们概述了葡萄牙 PRISM 队列中 PD 的人口统计学、临床特征和影响。
对 PRISM 葡萄牙队列（80 例患者）进行描述性分析，强调社会人口统计学数据、抗 PD 药物使用、PD 对患者生活的影响以及医疗资源的利用。
葡萄牙 PD 队列（55%男性；平均年龄 66.2 岁；平均病程 8.8 年）的主要合并症包括抑郁（26.3%）和焦虑（26.3%）。左旋多巴是 88%患者初始开的抗 PD 药物。在葡萄牙 PD 患者中，多巴胺激动剂（DA）、单胺氧化酶-B（MAO-B）抑制剂和儿茶酚-O-甲基转移酶（COMT）抑制剂的使用率分别为 50%、44.4%和 18.3%。葡萄牙 PD 患者的生活质量受损（PDQ-39 评分：31.3±16.8），存在各种非运动症状，如悲伤/忧郁（65.4%）、尿急（63.5%）、高/低性兴趣（57.7%），同时 56%的患者报告至少有一种冲动控制行为。此外，30.8%的患者因 PD 提前退休，31.8%的患者减少了日常活动时间。31%的患者接受了心理健康预约，主要在精神病学（19%）和心理学（6%）和心理治疗。
这项研究揭示了葡萄牙 PD 患者的负担，揭示了目前的治疗方法、对日常生活的影响以及葡萄牙使用的医疗资源。它强调了在国家和国际层面制定个性化临床策略的必要性，以改善 PD 患者的长期健康结果和生活质量。
